Hospital Canselor Tuanku Muhriz UKM or HCTM, formerly known as Hospital Universiti Kebangsaan Malaysia, is one of the five university hospitals in Malaysia. It is located in Bandar Tun Razak, Kuala Lumpur and is administered by Universiti Kebangsaan Malaysia.

During the past decade, Pusat Perubatan Universiti Kebangsaan Malaysia conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 7 clinical trials were completed, i.e. on average, 21.9% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 5 clinical trials were completed. i.e. 31.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Pusat Perubatan Universiti Kebangsaan Malaysia" #1 sponsor was "National University of Malaysia" with 10 trials, followed by "Universiti Kebangsaan Malaysia Medical Centre" with 10 trials sponsored, "Bayer" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Galapagos NV" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pusat Perubatan Universiti Kebangsaan Malaysia" #1 collaborator was "Cytopeutics Sdn. Bhd." with 2 trials as a collaborator, "Gilead Sciences" with 2 trials as a collaborator, "B-Crobes Laboratory (M) Sdn Bhd" with 1 trials as a collaborator, "Basilea Pharmaceutica" with 1 trials as a collaborator and "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Pusat Perubatan Universiti Kebangsaan Malaysia" are "Ulcerative Colitis" (5 trials), "Atrial Fibrillation" (2 trials), "Crohn's Disease" (2 trials), "Gestational Diabetes" (2 trials) and "Antibody" (1 trials). Many other conditions were trialed in "Pusat Perubatan Universiti Kebangsaan Malaysia" in a lesser frequency.

Most popular intervention types in "Pusat Perubatan Universiti Kebangsaan Malaysia" are "Drug" (24 trials), "Other" (7 trials), "Device" (5 trials), "Biological" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Autologous bone marrow-derived mesenchymal stem cells" (2 trials), "Etrolizumab" (2 trials), "Filgotinib" (2 trials) and "Mirikizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Pusat Perubatan Universiti Kebangsaan Malaysia" are 32 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Pusat Perubatan Universiti Kebangsaan Malaysia". undefined are not yet recruiting, 7 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 22 completed trials in Pusat Perubatan Universiti Kebangsaan Malaysia, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Pusat Perubatan Universiti Kebangsaan Malaysia, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 10 trials that are defined as “Not Applicable".